What is SVA (SVA) stock price today?

SVA (SVA) is currently trading at $6.47, up 0% today.

What is SVA P/E ratio?

SVA's P/E ratio is -6.10. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is SVA return on equity (ROE)?

SVA's return on equity (ROE) is -1.15%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is SVA's market cap?

SVA has a market capitalization of $464.94M.

NASDAQ · Biotechnology

SVA (SVA) Stock

$6.47 +0.00% NASDAQ: SVA Healthcare

Valuation

Metric	Value
Price	$6.47
Market Cap	$464.94M
P/E Ratio	-6.10
P/B Ratio	0.05
P/S Ratio	1.04
EPS (TTM)	$-1.06
52-Week High	$6.47
52-Week Low	$6.47
Dividend Yield	17.00%

Financials & Margins

Metric	Value
ROE	-1.15%
ROA	-0.73%
ROCE	-4.55%
Gross Margin	-122.10%
Operating Margin	-122.10%
Net Margin	-22.29%
Debt/Equity	0.03
Current Ratio	10.31

Annual Financials (USD)

Metric	2019	2020	2021	2022	2023
Revenue	$246.0M	$511.0M	$19.4B	$1.5B	$448.0M
Operating Profit	$69.0M	$216.0M	$17.6B	$-466.0M	$-547.0M
Net Profit	$45.0M	$110.0M	$8.5B	$114.0M	$-100.0M
EPS	$0.41	$0.97	$74.27	$1.00	$-1.06
Op Margin	27.9%	42.2%	90.6%	-31.2%	-122.0%

Balance Sheet (USD)

Metric	2019	2020	2021	2022	2023
Total Assets	$452.0M	$1.9B	$16.7B	$14.1B	$13.7B
Total Liabilities	$100.0M	$781.0M	$2.9B	$1.4B	$1.6B
Cash	$153.0M	$1.0B	$11.6B	$4.3B	$1.3B
Borrowings	$20.0M	$136.0M	$145.0M	$75.0M	$299.0M

Latest News

SINOVAC Regained Compliance With the Nasdaq Global Market’s Listing Requirements Business Wire · Jun 15, 2026 SINOVAC Reports Unaudited and Unreviewed Second Half of 2025 Financial Results and Files 2025 Annual Report on Form 20-F Business Wire · Jun 5, 2026 SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report Business Wire · May 29, 2026

Cash Flow (USD)

Metric	2019	2020	2021	2022	2023
Operating Cash Flow	$39.0M	$479.0M	$15.4B	$-771.0M	$104.0M
Investing Cash Flow	$-53.0M	$-332.0M	$-3.7B	$-6.2B	$-3.1B
Financing Cash Flow	$1.0M	$17.0M	$4.0M	$26.0M	$12.0M
Net Cash Flow	$-2.0M	$894.0M	$10.6B	$-7.3B	$-3.0B
Free Cash Flow	$28.0M	$352.0M	$14.6B	$-1.2B	$-42.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-8.97%
Quick Ratio	10.18
Interest Coverage	-273.50
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BCYPBig Cypress Acquisition Corp.	$8.44	-19.23%	19.63	$425.36M	0.00%
CKPTCheckpoint Therapeutics, Inc.	$4.26	+0.00%	-3.00	$367.72M	0.00%
GTHXG1 Therapeutics, Inc.	$7.16	+0.14%	-7.70	$377.75M	0.00%
ITOSiTeos Therapeutics, Inc.	$10.15	+0.20%	-3.89	$448.68M	0.00%
IVVD	$0.55	+3.10%	-3.53	$162.51M	0.00%

About SVA

SVA is led by CEO Wei Dong Yin, employs 1,959 people, headquartered in CN, publicly traded since 2003.

SVA stock trades at $6.47 with a market capitalization of $464.94M. The stock is valued at a price-to-earnings (P/E) ratio of -6.10, price-to-book of 0.05, price-to-sales of 1.04. Over the past 52 weeks the stock has ranged between $6.47 and $6.47, and currently trades at its 52-week high. It pays a dividend yielding 17.00%.

On profitability, SVA generates a return on equity (ROE) of -1.15%, return on capital employed of -4.55%, an operating margin of -122.10%, a net profit margin of -22.29%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides